January 19, 2016

Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer

Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of… Read More
learn more
January 19, 2016

Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer

Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of… Read More
learn more
January 19, 2016

Novocure Presents Phase 2 PANOVA Results at ASCO GI Suggesting Tumor Treating Fields Therapy Plus Chemotherapy may be Safe as First-Line Treatment and Improve Survival of Patients with Advanced Pancreatic Cancer

Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of gemcitabine-treated historical controls Progression free survival and overall survival of patients treated with Tumor Treating Fields combined with gemcitabine were more than double those of… Read More
learn more
January 11, 2016

Novocure Announces Preliminary 2015 Operating Statistics

555 prescriptions were received in the fourth quarter of 2015, an increase of 108% versus the prior year quarter 603 active patients at December 31, 2015, an increase of 168% versus December 31, 2014 January 11, 2016 07:30 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More
learn more
January 11, 2016

Novocure Announces Preliminary 2015 Operating Statistics

555 prescriptions were received in the fourth quarter of 2015, an increase of 108% versus the prior year quarter 603 active patients at December 31, 2015, an increase of 168% versus December 31, 2014 January 11, 2016 07:30 AM Eastern Standard Time ST. HELIER, Jersey–(… Read More
learn more
January 7, 2016

Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients

January 07, 2016 04:15 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Optune,… Read More
learn more
January 7, 2016

Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients

January 07, 2016 04:15 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Optune,… Read More
learn more
January 7, 2016

Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients

January 07, 2016 04:15 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it submitted a premarket approval (PMA) partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the use of Optune,… Read More
learn more
January 6, 2016

Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System

Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune January 06, 2016 08:24… Read More
learn more
January 6, 2016

Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System

Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune Second generation Tumor Treating Fields delivery system is more than 50 percent lighter and 50 percent smaller than first generation Optune January 06, 2016 08:24… Read More
learn more